Stock Price Quote

TORRENT PHARMACEUTICALS LTD.

NSE : TORNTPHARMBSE : 500420ISIN CODE : INE685A01028Industry : Pharmaceuticals & DrugsHouse : Torrent
BSE4260.45186.4 (+4.58 %)
PREV CLOSE ( ) 4074.05
OPEN PRICE ( ) 4154.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 68325
TODAY'S LOW / HIGH ( )4130.00 4322.80
52 WK LOW / HIGH ( )2891.45 4239.95
NSE4261.50183.5 (+4.5 %)
PREV CLOSE( ) 4078.00
OPEN PRICE ( ) 4144.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 4261.50 (74)
VOLUME 1639922
TODAY'S LOW / HIGH( ) 4118.00 4324.90
52 WK LOW / HIGH ( )2886.45 4130
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-07 1972
Management Info
Samir Mehta - Chairman Aman Mehta - Managing Director
Registered Office

Address Avirat,Thaltej Shilaj Road, ,
Ahmedabad,
Gujarat-380059

Phone 079-26599000

Email investorservices@torrentpharma.com

Website www.torrentpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

13Feb Torrent Pharmaceuticals reports 26% ri
Torrent Pharmaceuticals has reported results for third quarter ended Dec..
02Feb Torrent Pharmaceuticals informs about
Torrent Pharmaceuticals has informed that a meeting of the Board of Dire..
27Jan Torrent Pharmaceuticals rises on acqui
Torrent Pharmaceuticals is currently trading at Rs. 3967.70, up by 40.75..
24Jan Torrent Pharmaceuticals acquires stake
Torrent Pharmaceuticals has acquired 37,82,566 equity shares of J.B. Che..
06Jan Torrent Pharmaceuticals gets nod to ra
Torrent Pharmaceuticals has received approval from Securities Transfer a..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit577018880
Gross Profit 7570 26100
Operating Profit 992036070
Net Sales 2599096820

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  13242.00 (1.52%)
M.Cap ( in Cr)16989.34
Procter&Gamble Healt (BSE)
peergroup  5061.35 (1.72%)
M.Cap ( in Cr)8401.53
JB Chem & Pharma (BSE)
peergroup  1977.85 (4.50%)
M.Cap ( in Cr)31749.94
Alkem Laboratories (BSE)
peergroup  5480.30 (1.46%)
M.Cap ( in Cr)65525.21
Natco Pharma (BSE)
peergroup  882.55 (7.35%)
M.Cap ( in Cr)15807.34

Shareholding Pattern

PROMOTERS 68.31%
NON-INSTITUTION 6.42%
MUTUAL FUNDS/UTI 4.83%
FI/BANKS/INSURANCE 1.72%
GOVERNMENT 0%
FII 0%

About Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd. was incorporated in the year 1972. Its today's share price is 4260.45. Its current market capitalisation stands at Rs 144192.99 Cr. In the latest quarter, company has reported Gross Sales of Rs. 98940 Cr and Total Income of Rs.97139.7 Cr. The company's management includes Chintan Trivedi, Aman Mehta, Jinal Mehta, Nikhil Khattau, Manish Choksi, Nayantara Bali, Ameera Shah, Samir Mehta.

It is listed on the BSE with a BSE Code of 500420 , NSE with an NSE Symbol of TORNTPHARM and ISIN of INE685A01028. It's Registered office is at Avirat,Thaltej Shilaj Road, Ahmedabad-380059, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, CC Chokshi & Co, Deloite Haskins & Sells, Deloitte Haskins & Sells, Deloittee Haskins & Sells

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.